Aptahem AB (publ) (NGM: APTA)

Market Cap	7.25M
Revenue (ttm)	2.65M
Net Income (ttm)	-11.22M
Shares Out	5.67M
EPS (ttm)	-2.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,402
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	1.510 - 28.000
Beta	1.17
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2024

About Aptahem AB

Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network. Aptahem AB (publ) was incorporated in 2014 and is based in M...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 4
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: APTA

Financial Performance

In 2023, Aptahem AB's revenue was 2.63 million, a decrease of -23.71% compared to the previous year's 3.45 million. Losses were -11.11 million, 25.4% more than in 2022.